MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.2016.70.3108

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017

Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.

Fung Chunkit, Sesso Howard D, Williams Annalynn M, Kerns Sarah L, Monahan Patrick, Abu Zaid Mohammad, Feldman Darren R, Hamilton Robert J, Vaughn David J, Beard Clair J, Kollmannsberger Christian K, Cook Ryan, Althouse Sandra, Ardeshir-Rouhani-Fard Shirin, Lipshultz Steve E, Einhorn Lawrence H, Fossa Sophie D, Travis Lois B, Platinum Study Group

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

Purpose To provide new information on adverse health outcomes (AHOs) in testicular cancer survivors (TCSs) after four cycles of etoposide and cisplatin (EPX4) or three or four cycles of bleomycin, etoposide, cisplatin (BEPX3/BEPX4). Methods Nine hundred fifty-two TCSs > 1 year postchemotherapy underwent physical examination and completed a questionnaire. Multinomial logistic regression estimated AHOs odds ratios (ORs) in relation to age, cumulative cisplatin and/or bleomycin dose, time since chemotherapy, sociodemographic factors, and health behaviors. Results Median age at evaluation was 37 years; median time since chemotherapy was 4.3 years. Chemotherapy consisted largely of BEPX3 (38.2%), EPX4 (30.9%), and BEPX4 (17.9%). None, one to two, three to four, or five or more AHOs were reported by 20.4%, 42.0%, 25.1%, and 12.5% of TCSs, respectively. Median number after EPX4 or BEPX3 was two (range, zero to nine and zero to 11, respectively; P > .05) and two (range, zero to 10) after BEPX4. When comparing individual AHOs for EPX4 versus BEPX3, Raynaud phenomenon (11.6% v 21.4%; P < .01), peripheral neuropathy (29.2% v 21.4%; P = .02), and obesity (25.5% v 33.0%; P = .04) differed. Larger cumulative bleomycin doses (OR, 1.44 per 90,000 IU) were significantly associated with five or more AHOs. Increasing age was a significant risk factor for one to two, three to four, or five or more AHOs versus zero AHOs (OR, 1.22, 1.50, and 1.87 per 5 years, respectively; P < .01); vigorous physical activity was protective (OR, 0.62, 0.51, and 0.41, respectively; P < .05). Significant risk factors for three to four and five or more AHOs included current (OR, 3.05 and 3.73) or former (OR, 1.61 and 1.76) smoking ( P < .05). Self-reported health was excellent/very good in 59.9% of TCSs but decreased as AHOs increased ( P < .001). Conclusion Numbers of AHOs after EPX4 or BEPX3 appear similar, with median follow-up of 4.3 years. A healthy lifestyle was associated with reduced number of AHOs.

Для цитирования: Fung Chunkit, Sesso Howard D, Williams Annalynn M, Kerns Sarah L, Monahan Patrick, Abu Zaid Mohammad, Feldman Darren R, Hamilton Robert J, Vaughn David J, Beard Clair J, Kollmannsberger Christian K, Cook Ryan, Althouse Sandra, Ardeshir-Rouhani-Fard Shirin, Lipshultz Steve E, Einhorn Lawrence H, Fossa Sophie D, Travis Lois B, Platinum Study Group. Multi-Institutional Assessment of Adverse Health Outcomes Among North American Testicular Cancer Survivors After Modern Cisplatin-Based Chemotherapy.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017. DOI: 10.1200/jco.2016.70.3108.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.